EXHIBIT 10.1

ANTARES PHARMA, INC.

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and
entered into on this 30th day of June 2016 (the “Effective Date”) by and between
Antares Pharma, Inc., a Delaware corporation (the “Company”), and James E.
Fickenscher (the “Executive”).

WITNESSETH:

WHEREAS, the Company and the Executive are parties to the Employment Agreement
dated November 17, 2014 (the “Prior Agreement”); and

WHEREAS, the Company and the Executive desire to amend and restate the Prior
Agreement to reflect certain severance enhancements and to make certain other
desired changes, pursuant to the terms and subject to the conditions hereinafter
set forth.

NOW, THEREFORE, in consideration of the premises and of the mutual promises and
covenants contained herein, the Company and the Executive, intending to be
legally bound, hereby agree as follows:

1. Employment.

(a) Term. This Agreement shall be effective as of the Effective Date and
continue until the one-year anniversary thereof, unless sooner terminated by
either party as hereinafter provided.  In addition, this Agreement shall
automatically renew for periods of one (1) year unless either party gives
written notice to the other party at least ninety (90) days prior to the end of
the Term (as defined below) or at least ninety (90) days prior to the end of any
one (1) year renewal period that the Agreement shall not be further
extended.  The period commencing on the Effective Date and ending on the date on
which the term of the Executive’s employment under this Agreement terminates is
referred to herein as the “Term.”  

(b) Duties.  During the Term, the Executive shall be employed by the Company as
the Senior Vice President, Chief Financial Officer with the duties,
responsibilities and authority commensurate therewith.  The Executive shall
report to the Chief Executive Officer (the “CEO”) and shall perform all duties
and accept all responsibilities incident to such position as may be reasonably
assigned to him by the CEO.

(c) Best Efforts.  During the Term, the Executive shall devote his best efforts
and full time and attention to promote the business and affairs of the Company,
and may not, without the prior written consent of the Company, operate,
participate in the management, operations or control of, or act as an employee,
officer, consultant, agent or representative of, any type of business or service
(other than as an employee of the Company).  It shall not be deemed a violation
of the foregoing for the Executive to (i) act or serve as a director, trustee or
committee member of any civic or charitable organization; (ii) manage his
personal, financial and legal affairs; or (iii) serve as a director of an
organization that is not a civic or charitable organization with the prior
consent of the Board of Directors of the Company (the “Board”), which consent
shall not be unreasonably withheld, in all cases so long as such activities
(described in clauses (i), (ii) and (iii)) are permitted under the Company’s
code of conduct and employment policies and do not materially interfere with or
conflict with his obligations to the Company hereunder, including, without
limitation, obligations pursuant to Section 6 below.

 

--------------------------------------------------------------------------------

 

2. Compensation.

(a) Base Salary.  During the Term, the Company shall pay the Executive a base
salary (“Base Salary”) at the annual rate of $364,000, which shall be paid in
accordance with the Company’s normal payroll practices.  The Executive’s Base
Salary shall be subject to review, and at the approval of the Compensation
Committee of the Board (the “Compensation Committee”), subject to increase (but
not decrease) during the Term, based upon the performance of the Executive and
the Company, as determined by the Compensation Committee with input from the
CEO, in accordance with the Company’s normal compensation and performance review
policies for senior executives generally.  

(b) Bonus.  In addition to the Executive’s Base Salary, the Executive shall be
eligible to receive a bonus for each calendar year during the Term, based on
attainment of certain individual and corporate performance goals and targets
(the “Annual Bonus”) in accordance with the terms of the Company’s Annual
Incentive Plan, as amended from time to time (or successor plan).  The target
amount of the Executive’s Annual Bonus shall be 40% of Base Salary.  The
performance goals and targets shall be determined by the Compensation Committee
in consultation with the CEO.  Once determined, the applicable performance goals
and targets shall be communicated to the Executive as soon as reasonably
practicable following the Compensation Committee’s determination of the
applicable goals and targets.  The actual Annual Bonus amount paid will be based
upon the Compensation Committee’s determination, in its sole discretion, whether
and to what extent the applicable performance goals and targets have been
achieved, and such amount may be more or less than the target amount, as
determined by the Compensation Committee in its sole discretion.  Any Annual
Bonus earned and payable to the Executive hereunder shall be paid on or after
January 1 but not later than March 15 of the calendar year following the
calendar year for which the Annual Bonus is earned.  

(c) Equity Compensation.  During the Term, the Executive shall be eligible to
participate in any long-term equity incentive programs established by the
Company for its senior level executives generally, including the Antares Pharma,
Inc. 2008 Equity Compensation Plan, as amended from time to time (the “2008
Equity Plan”) (or successor plan), at levels determined by the Compensation
Committee in its sole discretion, commensurate with the Executive’s position.

(d) Vacation.  During the Term, the Executive shall be entitled to vacation,
holiday and sick leave at levels generally commensurate with those provided to
other senior executives of the Company, in accordance with the Company’s
vacation, holiday and other pay-for-time-not worked policies; provided, however,
that the Executive shall be entitled to not less than four (4) weeks of paid
vacation each calendar year, prorated from any period of employment of less than
twelve (12) months in a calendar year.  Such paid time off may be carried over
from year to year to the extent permitted in accordance with standard Company
policy and shall be paid to the extent accrued (and to the extent not used) as
of the Executive’s termination of employment.

(e) Employee Benefits.  The Executive shall be entitled to participate in the
Company’s health, life insurance, long and short-term disability, dental,
retirement, savings, flexible spending accounts and medical programs, if any,
pursuant to their respective terms and conditions.  Nothing in this Agreement
shall preclude the Company or any parent, subsidiary or affiliate of the Company
from terminating or amending any employee benefit plan or program from time to
time after the Effective Date.

(f) Expense Reimbursement.  During the Term, the Company shall reimburse the
Executive, in accordance with the policies and practices of the Company in
effect from time to time, for all reasonable and necessary business expenses and
other disbursements incurred by him for or on behalf of the Company in
connection with the performance of his duties hereunder upon presentation by the
Executive to the Company of appropriate documentation thereof.

2

--------------------------------------------------------------------------------

 

3. Termination of Employment.

(a) Termination for Cause.  The Company may terminate the Executive’s employment
hereunder at any time for Cause (as defined below) upon written notice to the
Executive (as described below), in which event all payments under this Agreement
shall cease, except for any amounts earned, accrued and owing, but not yet paid
under Section 2 above and any benefits accrued and due under any applicable
benefit plans and programs of the Company.  

For purposes of this Agreement, the term “Cause” shall mean any of the following
grounds for termination of the Executive’s employment: (i) the Executive’s
knowing and material dishonesty or fraud committed in connection with the
Executive’s employment; (ii) theft, misappropriation or embezzlement by the
Executive of the Company’s funds; (iii) the Executive’s conviction of or a plea
of guilty or nolo contendere to any felony, a crime involving fraud or
misrepresentation, or any other crime (whether or not connected with his
employment) the effect of which is likely to adversely affect the Company or its
parents, subsidiaries or affiliates; or (iv) a material breach by the Executive
of any of the provisions or covenants set forth in this Agreement.

(b) Voluntary Resignation.  The Executive may voluntarily terminate his
employment without Good Reason (as defined below) upon thirty (30) days advance
written notice to the Company.  In such event, after the effective date of such
termination, no payments shall be due under this Agreement, except that the
Executive shall be entitled to any amounts earned, accrued and owing, but not
yet paid under Section 2 above and any benefits accrued and due under any
applicable benefit plans and programs of the Company.  

For purposes of this Agreement, “Good Reason” shall mean the occurrence of one
or more of the following without the prior written consent of the Executive: (i)
a material reduction in Executive’s Base Salary; (ii) the Company’s material
breach of terms of this Agreement (which for purposes of this Agreement shall
include (A) the failure of the Company to require any successor to the Company
to assume the obligations of the Company to Executive under this Agreement and
any other agreement between the Company and Executive then in effect or (B) the
Company’s reduction in the target annual bonus opportunity below forty (40%) of
Base Salary for any calendar year during the Term) (for the avoidance of doubt
for purposes of this clause (ii), both of the events described in subclauses (A)
and (B) do not need to occur for a material breach of this Agreement to be
triggered); (iii) a change in the Executive’s designation of title from Senior
Vice President, Chief Financial Officer of the Company or successor entity
(unless such change is to a higher title and level of responsibility) that
results in a material diminution in Executive’s authority, duties and
responsibilities; (iv) a material change in the geographic location at which
Executive must perform services that results in the relocation of Executive’s
principal business location to a location that is sixty (60) miles or more from
Ewing, New Jersey; or (v) the Company’s delivery to the Executive of a notice of
its intent not to renew the Term pursuant to Section 1(a) above; provided that
the Executive is willing and able to execute a new contract providing terms and
conditions substantially similar to those in this Agreement and to continue
providing services to the Company.  

Notwithstanding any provision of this definition of Good Reason to the contrary,
the Executive shall not have Good Reason for termination unless the Executive
gives written notice of termination for Good Reason within thirty (30) days
after the event giving rise to Good Reason occurs, the Company does not correct
the action or failure to act that constitutes the grounds for Good Reason, as
set forth in the Executive’s notice of termination, within thirty (30) days
after the date on which the Executive gives written notice of termination, and
the Executive terminates employment within sixty (60) days after the event that
constitutes Good Reason.  If the Executive’s resignation occurs after such time,
the resignation shall be treated as a voluntary resignation other than for Good
Reason and the Executive will not be entitled to severance benefits under this
Agreement.

3

--------------------------------------------------------------------------------

 

(c) Termination without Cause; Resignation for Good Reason.  Except as provided
in Section 4(a) below, if the Executive’s employment is terminated by the
Company (or the surviving company following a Change of Control (as defined in
Section 4(c) below)) without Cause or by the Executive for Good Reason, either
before or after a Change of Control, the provisions of this Section 3(c) shall
apply (subject to the modifications of Section 4(a) below, if applicable).  The
Company may terminate the Executive’s employment with the Company at any time
without Cause upon not less than thirty (30) days’ prior written notice to the
Executive.  The Company may, in its sole and absolute discretion, pay the
Executive his Base Salary in lieu of any unexpired period of notice and
terminate his employment immediately.  Except as provided in Section 4(a) below,
upon termination of the Executive ’s employment by the Company under this
Section 3(c) or by the Executive for Good Reason, either before or after a
Change of Control, if the Executive executes and does not revoke a written
release, in substantially the form attached hereto as Exhibit A, of any and all
claims against the Company and all related parties with respect to all matters
arising out of the Executive’s employment by the Company, or the termination
thereof (other than claims for any entitlements under the terms of this
Agreement or under any plans or programs of the Company under which the
Executive has accrued and is due a benefit) (the “Release”), and continues to
comply with the provisions of the Proprietary Information and Invention
Assignment Agreement (as defined in Section 6(a) below) and restrictive
covenants and representations in Section 6 below, the Executive shall be
entitled to receive the payments and benefits set forth in subsections 3(c)(i),
(ii) and (iii), in lieu of any other payments and benefits due under any
severance plan or program for employees or executives (subject to the
modifications of Section 4(a) below, if applicable).  Notwithstanding any
provision of this Agreement to the contrary, in no event shall the timing of the
Executive’s execution of the Release, directly or indirectly, result in the
Executive designating the calendar year of payment, and if a payment that is
subject to execution of the Release could be made in more than one taxable year,
payment shall be made in the later taxable year.

(i) The Company will pay to the Executive severance as follows:  the rate of the
Executive’s Base Salary as in effect at the time of termination will be added
together with the dollar value of the Executive’s target Annual Bonus for the
year in which termination occurs and the sum of the foregoing amounts will be
divided by twelve (12) (the “Monthly Severance Amount”).  The Monthly Severance
Amount will be paid each month over the twelve (12) month period following the
Termination Date, less applicable tax withholding, paid in approximately equal
installments beginning within the sixty (60)-day period following the date of
the Executive’s termination of employment and continuing on each payroll date
thereafter until fully paid, in accordance with the Company’s regular payroll
practices.  The first severance payment will include any missed payments during
such sixty (60)-day period.

(ii) The Company will pay to the Executive a pro rata Annual Bonus for the year
in which the termination of employment occurs, which shall be determined based
on Executive’s actual Annual Bonus earned for the year in which termination of
employment occurs (if any), based on actual performance, multiplied by a
fraction, the numerator of which is the number of days in which the Executive
was employed by Company during the year in which the termination of employment
occurs, and the denominator of which is three hundred sixty-five (365).  The pro
rata Annual Bonus described in this subsection 3(c)(ii) will be paid at the same
time and under the same terms and conditions as bonuses are paid to other
executives of the Company, on or after January 1 but not later than March 15 of
the calendar year following the calendar year in which the Executive’s
employment terminates, subject to Section 5(b) below.  

(iii) For the twelve (12) month period following the Executive’s termination of
employment, provided that the Executive timely elects COBRA, the Company will
reimburse the Executive for the monthly COBRA cost of continued medical and
dental coverage for the Executive and, where applicable, his spouse and
dependents, at the level in effect as of the date of the Executive’s termination
of employment, less the employee portion of the applicable premiums that the
Executive would have paid had he remained employed during the

4

--------------------------------------------------------------------------------

 

such twelve (12) month period (the COBRA continuation coverage period shall run
concurrently with the twelve (12) month period that the Executive is provided
with medical and dental coverage under subsection 3(c)(i)).  These
reimbursements will commence within the sixty (60)-day period following the date
of the Executive’s termination of employment and will be paid on the first
payroll date of each month, provided that the Executive demonstrates proof of
payment of the applicable premiums prior to the applicable reimbursement payment
date.  Notwithstanding the foregoing, the Company’s reimbursement of the monthly
COBRA premiums in accordance with this subsection 3(c)(iii) shall cease
immediately upon the earlier of:  (A) the end of the twelve (12) month period
following the Executive’s termination of employment, or (B) the date that the
Executive is eligible for comparable coverage with a subsequent
employer.  Notwithstanding the foregoing, the Company reserves the right to
restructure the foregoing COBRA premium reimbursement  arrangement in any manner
necessary or appropriate to avoid fines, penalties or negative tax consequences
to the Company or the Executive (including, without limitation, to avoid any
penalty imposed for violation of the nondiscrimination requirements under the
Patient Protection and Affordable Care Act or the guidance issued thereunder),
as determined by the Company in its sole and absolute discretion.

(iv) Notwithstanding any provision to the contrary in the 2008 Equity Plan (or a
successor plan) or any applicable agreement (including this Agreement), all
outstanding equity grants held by the Executive immediately prior to the
Executive’s termination date which vest based upon the Executive’s continued
service over time that would have become vested during the twelve (12) month
period following the Executive’s termination date had the Executive remained
employed during such twelve (12) month period shall accelerate, become fully
vested and/or exercisable, as the case may be, as of the Executive’s termination
date.  All outstanding equity grants held by the Executive immediately prior to
the Executive’s termination date which vest based upon attainment of performance
criteria shall remain subject to the terms and conditions of the agreement
evidencing such performance based award.  In addition, any outstanding vested
options held by the Executive as of his termination date shall remain
exercisable by the Executive through the earlier of the six (6) month
anniversary of the Executive’s termination date or the date of expiration of the
option term.  

(v) The Executive shall also be entitled to any amounts earned, accrued and
owing but not yet paid under Section 2 above and any benefits accrued and due
under any applicable benefit plans and programs of the Company without regard to
whether the Executive does not execute or revokes the Release.

(d) Death or Disability.  The Executive’s employment hereunder shall terminate
upon the Executive’s death or involuntary termination of employment by the
Company on account of his Disability (as defined below), subject to the
requirements of applicable law.  If the  Executive’s employment terminates due
to death or involuntary termination by the Company on account of the Executive’s
Disability, no payments shall be due under this Agreement, except that the
Executive (or in the event of the Executive’s death, the Executive’s executor,
legal representative, administrator or designated beneficiary, as applicable),
shall be entitled to receive any amounts earned, accrued and owing but not yet
paid under Section 2 above and any benefits accrued and due under any applicable
benefit plans and programs of the Company.  For purposes of this Agreement, the
term “Disability” shall mean such physical or mental illness or incapacity of
the Executive as shall (i) prevent him from substantially performing his
customary services and duties to the Company, and (ii) continue for periods
aggregating more than sixty (60) days in any six (6)-month period.  The Company
shall determine whether there is a Disability after consultation with a
qualified, independent physician.  The Executive shall cooperate with the
Company, including making himself reasonably available for examination by
physicians at the Company’s request, to determine whether or not he has incurred
a Disability.  The Executive’s failure (other than a failure caused by the
Disability) to cooperate with the Company in a determination of Disability shall
be treated as the Executive’s voluntary resignation from the Company without
Good Reason.

5

--------------------------------------------------------------------------------

 

4. Change of Control.  

(a) Termination without Cause or Resignation for Good Reason Within Sixty Days
Before or Eighteen Months Following a Change of Control.  Notwithstanding
anything to the contrary herein, if there is both a Change of Control and the
Executive’s employment is terminated without Cause or by the Executive for Good
Reason within sixty (60) days before or within eighteen (18) months following
such Change of Control (a “CIC Termination”), the Executive shall be entitled to
(i) the payments set forth under subsection 3(c)(i), except that the Monthly
Severance Amount will be multiplied by eighteen (18) months, (ii) the payment
described in subsection 3(c)(ii) on the same terms and conditions described in
subsection 3(c)(ii), (iii) the payments set forth under subsection 3(c)(iii),
except that twelve (12) months shall be replaced with eighteen (18) months, and
(iv) in lieu of the benefit described in subsection 3(c)(iv), notwithstanding
any provision to the contrary in the 2008 Equity Plan (or a successor plan) or
any applicable agreement (including this Agreement), all outstanding equity
grants held by the Executive immediately prior to the CIC Termination which vest
based upon the Executive’s continued service over time shall accelerate, become
fully vested and/or exercisable, as the case may be, as of the date of the CIC
Termination and all outstanding equity grants held by the Executive immediately
prior to the CIC Termination which vest based upon attainment of performance
criteria shall remain subject to the terms and conditions of the agreement
evidencing such performance based award.  Notwithstanding the foregoing in this
Section 4(a), no amounts under this Section 4(a) will be paid or benefits under
this Section 4(a) will be provided, in each case, upon a CIC Termination unless
the Executive executes and does not revoke a Release and continues to comply
with the covenants set forth in Section 6 below and the provisions of any
confidentiality, non-competition, non-solicitation or invention assignment
agreement with the Company to which the Executive is subject.

(b) Application of Section 280G.  In the event that it shall be determined that
any payment or distribution in the nature of compensation (within the meaning of
section 280G(b)(2) of the Internal Revenue Code of 1986, as amended (the
“Code”)) to or for the benefit of the Executive, whether paid or payable or
distributed or distributable pursuant to the terms of this Agreement or
otherwise (a “Payment”), would constitute an “excess parachute payment” within
the meaning of section 280G of the Code, the aggregate present value of the
Payments under the Agreement shall be reduced (but not below zero) to the
Reduced Amount (defined below), provided that the reduction shall be made only
if the Accounting Firm (described below) determines that the reduction will
provide the Executive with a greater net after-tax benefit than would no
reduction.  The “Reduced Amount” shall be an amount expressed in present value
which maximizes the aggregate present value of Payments under this Agreement
without causing any Payment under this Agreement to be subject to the Excise Tax
(defined below), determined in accordance with section 280G(d)(4) of the
Code.  The term “Excise Tax” means the excise tax imposed under section 4999 of
the Code, together with any interest or penalties imposed with respect to such
excise tax.  Payments under this Agreement shall be reduced on a
nondiscretionary basis in such a way as to minimize the reduction in the
economic value deliverable to the Executive.  Where more than one payment has
the same value for this purpose and they are payable at different times they
will be reduced on a pro rata basis. Only amounts payable under this Agreement
shall be reduced pursuant to this Section 4(b).  All determinations to be made
under this Section 4(b) shall be made by an independent certified public
accounting firm selected by the Company immediately prior to the Change of
Control (the “Accounting Firm”), which shall provide its determinations and any
supporting calculations both to the Company and the Executive within ten (10)
days of the Change of Control.  Any such determination by the Accounting Firm
shall be binding upon the Company and the Executive.  All of the fees and
expenses of the Accounting Firm in performing the determinations referred to in
this Section 4(b) shall be borne solely by the Company.

6

--------------------------------------------------------------------------------

 

(c) Definition of a Change of Control.  For purposes of this Agreement, the term
“Change of Control” shall have the same meaning ascribed to such term under the
2008 Equity Plan, as in effect on the date hereof and as it may be amended from
time to time, or if the 2008 Equity Plan is no longer in effect, a successor
plan thereto.  

5. Section 409A.

(a) Compliance with Section 409A.  This Agreement is intended to comply with
section 409A of the Code and its corresponding regulations, or an exemption, and
payments may only be made under this Agreement upon an event and in a manner
permitted by section 409A, to the extent applicable.  Severance benefits under
the Agreement are intended to be exempt from section 409A of the Code under the
“short-term deferral” exception, to the maximum extent applicable, and then
under the “separation pay” exception, to the maximum extent applicable.   For
purposes of section 409A of the Code, all payments to be made upon a termination
of employment under this Agreement may only be made upon a “separation from
service” within the meaning of such term under section 409A of the Code, each
payment made under this Agreement shall be treated as a separate payment and the
right to a series of installment payments under this Agreement is to be treated
as a right to a series of separate payments.  In no event shall the Executive,
directly or indirectly, designate the calendar year of payment.  All
reimbursements and in-kind benefits provided under this Agreement shall be made
or provided in accordance with the requirements of section 409A of the Code,
including, where applicable, the requirement that (i) any reimbursement is for
expenses incurred during the Executive’s lifetime (or during a shorter period of
time specified in this Agreement), (ii) the amount of expenses eligible for
reimbursement, or in-kind benefits provided, during a calendar year may not
affect the expenses eligible for reimbursement, or in-kind benefits to be
provided, in any other calendar year, (iii) the reimbursement of an eligible
expense will be made on or before the last day of the calendar year following
the year in which the expense is incurred, and (iv) the right to reimbursement
or in-kind benefits is not subject to liquidation or exchange for another
benefit.

(b) Payment Delay.  Notwithstanding any provision in this Agreement to the
contrary, if at the time of the Executive’s separation from service with the
Company, the Company has securities which are publicly traded on an established
securities market and the Executive is a “specified employee” (as defined in
section 409A of the Code) and it is necessary to postpone the commencement of
any severance payments otherwise payable pursuant to this Agreement as a result
of such separation from service to prevent any accelerated or additional tax
under section 409A of the Code, then the Company will postpone the commencement
of the payment of any such payments hereunder (without any reduction in such
payments ultimately paid or provided to the Executive) that are not otherwise
exempt from section 409A of the Code, until the first payroll date that occurs
after the date that is six (6) months following the Executive’s separation from
service with the Company.  If any payments are postponed due to such
requirements, such postponed amounts will be paid in a lump sum to the Executive
on the first payroll date that occurs after the date that is six (6) months
following the Executive’s separation from service with the Company.  If the
Executive dies during the postponement period prior to the payment of the
postponed amount, the amounts withheld on account of section 409A of the Code
shall be paid to the personal representative of the Executive’s estate within
sixty (60) days after the date of the Executive’s death.

7

--------------------------------------------------------------------------------

 

6. Restrictive Covenants and Representations.

(a) Confidential Information.  Contemporaneously with this Agreement, the
Executive executed the Company’ s standard Proprietary Information and Invention
Assignment Agreement, attached hereto as Exhibit B (the “Proprietary Information
and Invention Assignment Agreement”), all of the terms of which are hereby
incorporated into this Agreement by reference.  The Executive hereby agrees
that, during the Term and thereafter, the Executive shall hold in strict
confidence any proprietary or Confidential Information (as defined below)
related to the Company and its parents, subsidiaries and affiliates, except that
he may disclose such information pursuant to law, court order, regulation or
similar order or in accordance with Sections 6(g) and (h) below.  For purposes
of this Agreement, the term “Confidential Information” shall mean all
information of the Company or any of its parents, subsidiaries and affiliates
(in whatever form) which is not generally known to the public, including without
limitation any inventions, processes, methods of distribution, customer lists or
trade secrets.  The Executive hereby agrees that, upon the termination of this
Agreement, he shall not take, without the prior written consent of the Company
or in accordance with Sections 6(g) and (h) below, any document (in whatever
form) of the Company or its parents, subsidiaries or affiliates, which is of a
confidential nature relating to the Company or its parents, subsidiaries or
affiliates, or, without limitation, relating to its or their methods of
distribution, or any description of any formulas or secret processes and will
return any such information (in whatever form) then in his possession.

(b) Non-Competition.  The Executive hereby acknowledges that during his
employment with the Company, the Executive will become familiar with trade
secrets and other Confidential Information concerning the Company, its
subsidiaries and their respective predecessors, and that the Executive’s
services will be of special, unique and extraordinary value to the
Company.  Accordingly, the Executive hereby agrees that, subject to the
requirements of applicable law, at any time during the Term, and for a period of
twelve (12) months after the Executive’s date of termination of employment for
any reason except a CIC Termination, or eighteen (18) months after a CIC
Termination (such twelve (12) month period or eighteen (18) month period, as
applicable, shall be referred to as the “Restriction Period”), the Executive
will not, directly or indirectly, own, manage, control, participate in, consult
with, render services for, or in any manner engage in any business involving or
related to (directly or indirectly) the research, development, marketing and/or
sale or other delivery of injection devices, within any geographical area in
which, as of the date of the Executive’s termination of employment, the Company
or its subsidiaries engage in business or demonstrably plan to engage in
business (the “Business”).  It will not be considered a violation of this
Section 6(b) for the Executive to be a passive owner of not more than 1% of the
outstanding stock of any class of a corporation which is publicly traded, so
long as the Executive has no active participation in the business of such
corporation.  In addition, the restrictions contained in this section 6(b) shall
not prevent the Executive from accepting employment following termination of
employment with the Company with a large diversified organization with separate
and distinct divisions that do not compete, directly or indirectly, with the
Business, as long as prior to accepting such employment, the Company receives
separate written assurances from the prospective employer and from the
Executive, satisfactory to the Company, to the effect that Executive will not
render any services, directly or indirectly, to any division or business unit
that competes, directly or indirectly, with the Business.  During the
restrictive period set forth in the section, Executive will inform any new
employer, prior to accepting employment, of the existence of this Agreement and
provide such employer with a copy of this Agreement.

(c) Non-Solicitation.  The Executive hereby agrees that during the Term and the
Restriction Period, (i) the Executive will not, directly or indirectly through
another entity, induce or attempt to induce any employee of the Company or its
subsidiaries to leave the employ of the Company or its subsidiaries, or in any
way interfere with the relationship between the Company or its subsidiaries and
any employee thereof or otherwise employ or receive the services of an
individual who was an employee of the Company or its subsidiaries at any time
during such Restriction Period, except any such individual whose employment has
been terminated by the

8

--------------------------------------------------------------------------------

 

Company and (ii) the Executive will not induce or attempt to induce any
customer, supplier, client, broker, licensee or other business relation of the
Company or its subsidiaries to cease doing business with the Company or its
subsidiaries.

(d) Return of Property.  Upon termination of the Executive’s employment with the
Company for any reason whatsoever, voluntarily or involuntarily (and in all
events within five (5) days of the Executive’s date of termination), and at any
earlier time the Company requests, the Executive will deliver to the person
designated by the Company all originals and copies of all documents and property
of the Company in the Executive’s possession, under the Executive’s control or
to which the Executive may have access, including but not limited to, any
office, computing or communications equipment (e.g., laptop computer, facsimile
machine, printer, cellular phone, etc.) that he has had or has been using, and
any business or business-related files that he has had in his possession, except
as otherwise permitted in accordance with Sections 6(g) and (h) below.  The
Executive will not reproduce or appropriate for the Executive’s own use, or for
the use of others, any property, Confidential Information or Company inventions,
and shall remove from any personal computing or communications equipment all
information relating to the Company, except as otherwise permitted in accordance
with Sections 6(g) and (h) below.

(e) Non-Disparagement.  The Executive agrees that the Executive will not
disparage the Company, its subsidiaries and parents, and their respective
Executives, directors, investors, employees, and agents, and its and their
respective successors and assigns, heirs, executors, and administrators, or make
any public statement reflecting negatively on the Company, its subsidiaries and
parents, and their respective officers, directors, investors, employees, and
agents, and its and their respective successors and assigns, heirs, executors,
and administrators, to third parties, including, but not limited to, any matters
relating to the operation or management of the Company, irrespective of the
truthfulness or falsity of such statement, except as may otherwise be required
by applicable law or compelled by process of law, except as otherwise permitted
in accordance with Sections 6(g) and (h) below.  The Company shall instruct the
members of the Board and members of executive management not make any
disparaging or negative remarks, either oral or in writing, regarding the
Executive.

(f) Cooperation.  During the Term and thereafter, the Executive shall cooperate
with the Company and its parents, subsidiaries and affiliates, upon the
Company’s reasonable request, with respect to any internal investigation or
administrative, regulatory or judicial proceeding involving matters within the
scope of the Executive’s duties and responsibilities to the Company during the
Term (including, without limitation, the Executive being available to the
Company upon reasonable notice for interviews and factual investigations,
appearing at the Company’s reasonable request to give testimony without
requiring service of a subpoena or other legal process, and turning over to the
Company all relevant Company documents which are or may come into the
Executive’s possession during the Term); provided, however, that any such
request by the Company shall not be unduly burdensome or interfere with the
Executive’s personal schedule or ability to engage in gainful employment.  In
the event the Company requires the Executive’s cooperation in accordance with
this Section 6(f), the Company shall reimburse the Executive for reasonable
out-of-pocket expenses (including travel, lodging and meals and reasonable
attorneys’ fees) incurred by the Executive in connection with such cooperation,
subject to reasonable documentation.

(g) Reports to Government Entities.  Nothing in this Agreement or the
Proprietary Information and Invention Assignment Agreement, restricts or
prohibits the Executive from initiating communications directly with, responding
to any inquiries from, providing testimony before, providing Confidential
Information to, reporting possible violations of law or regulation to, or from
filing a claim or assisting with an investigation directly with a
self-regulatory authority or a government agency or entity, including the U.S.
Equal Employment Opportunity Commission, the Department of Labor, the National
Labor Relations Board, the

9

--------------------------------------------------------------------------------

 

Department of Justice, the Securities and Exchange Commission, the Congress, and
any agency Inspector General (collectively, the “Regulators”), or from making
other disclosures that are protected under the whistleblower provisions of state
or federal law or regulation.  The Executive does not need the prior
authorization of the Company to engage in such communications with the
Regulators, respond to such inquiries from the Regulators, provide Confidential
Information or confidential documents to the Regulators, or make any such
reports or disclosures to the Regulators.  The Executive is not required to
notify the Company that the Executive has engaged in such communications with
the Regulators.  If the Executive is required by law or judicial order to
disclose Confidential Information, other than to Regulators as described above,
the Executive shall give prompt written notice to the Company so as to permit
the Company the opportunity to limit or prevent any such disclosure and to
obtain an order of protection or confidentiality to protect its interests in the
Confidential Information to the extent possible.  Subject to the foregoing
sentence, Executive may furnish that portion (and only that portion) of the
Confidential Information that Executive is legally compelled or is otherwise
legally required to disclose; provided, however, that Executive provides such
assistance as Company may reasonably request in obtaining such order or other
relief.

(h) Notice of Immunity for Confidential Disclosure of a Trade Secret to an
Attorney, the Government or in a Court Filing.  Federal law provides certain
protections to individuals who disclose a trade secret to their attorney, a
court, or a government official in certain, confidential
circumstances.  Specifically, federal law provides that an individual shall not
be held criminally or civilly liable under any federal or state trade secret law
for the disclosure of a trade secret under either of the following conditions:

(i) Where the disclosure is made (A) in confidence to a Federal, State, or local
government official, either directly or indirectly, or to an attorney; and (B)
solely for the purpose of reporting or investigating a suspected violation of
law; or

(ii) Where the disclosure is made in a complaint or other document filed in a
lawsuit or other proceeding, if such filing is made under seal.  See 18 U.S.C. §
1833(b)(1)).

Federal law also provides that an individual who files a lawsuit for retaliation
by an employer for reporting a suspected violation of law may disclose the trade
secret to the attorney of the individual and use the trade secret information in
the court proceeding, if the individual (A) files any document containing the
trade secret under seal; and (B) does not disclose the trade secret, except
pursuant to court order.  See 18 U.S.C. § 1833(b)(2).

(i) Executive Representations.

(i) The Executive represents and warrants to the Company that there are no
restrictions, agreements or understandings whatsoever to which the Executive is
a party which would prevent or make unlawful the Executive’s execution of this
Agreement or the Executive’s employment hereunder, which is or would be
inconsistent or in conflict with this Agreement or the Executive’s employment
hereunder, or would prevent, limit or impair in any way the performance by the
Executive of the obligations hereunder.  In addition, the Executive has
disclosed to the Company all restraints, confidentiality commitments, and other
employment restrictions that he has with any other employer, person or
entity.  The Executive covenants that in connection with his provision of
services to the Company, the Executive shall not breach any obligation (legal,
statutory, contractual or otherwise) to any former employer or other person,
including, but not limited to, obligations relating to confidentiality and
proprietary rights.

(ii) Upon and after the Executive’s termination or cessation of employment with
the Company and until such time as no obligations of the Executive to the
Company hereunder exist, the Executive shall (A) provide a complete copy of this
Agreement to any person, entity or association engaged in a competing business
with whom or which the Executive proposes to be employed, affiliated, engaged,
associated or to establish any

10

--------------------------------------------------------------------------------

 

business or remunerative relationship prior to the commencement of any such
relationship and (B) shall notify the Company of the name and address of any
such person, entity or association prior to the commencement of such
relationship.

7. Legal and Equitable Remedies.  Because the Executive’s services are personal
and unique and the Executive has had and will continue to have access to and has
become and will continue to become acquainted with the proprietary information
of the Company, and because any breach by the Executive of any of the
restrictive covenants contained in Section 6 would result in irreparable injury
and damage for which money damages would not provide an adequate remedy, the
Company shall have the right to enforce Section 6 and any of its provisions by
injunction, specific performance or other equitable relief, without bond and
without prejudice to any other rights and remedies that the Company may have for
a breach, or threatened breach, of the restrictive covenants set forth in
Section 6.  The Executive agrees that in any action in which the Company seeks
injunction, specific performance or other equitable relief, the Executive will
not assert or contend that any of the provisions of Section 6 are unreasonable
or otherwise unenforceable.  The Executive irrevocably and unconditionally (a)
agrees that any legal proceeding arising out of this paragraph may be brought in
the United States District Court for the District of New Jersey, or if such
court does not have jurisdiction or will not accept jurisdiction, in any court
of general jurisdiction in Mercer County, New Jersey, (b) consents to the
non-exclusive jurisdiction of such court in any such proceeding, and (c) waives
any objection to the laying of venue of any such proceeding in any such
court.  The Executive also irrevocably and unconditionally consents to the
service of any process, pleadings, notices or other papers.

8. Arbitration; Expenses.  In the event of any dispute under the provisions of
this Agreement, other than a dispute in which the primary relief sought is an
equitable remedy such as an injunction, the parties shall be required to have
the dispute, controversy or claim settled by arbitration in Trenton, New Jersey
in accordance with the National Rules for the Resolution of Employment Disputes
then in effect of the American Arbitration Association, before an arbitrator
agreed to by both parties.  If the parties cannot agree upon the choice of
arbitrator, the Company and the Executive will each choose an arbitrator.  The
two arbitrators will then select a third arbitrator who will serve as the actual
arbitrator for the dispute, controversy or claim.  Any award entered by the
arbitrators shall be final, binding and nonappealable and judgment may be
entered thereon by either party in accordance with applicable law in any court
of competent jurisdiction.  This arbitration provision shall be specifically
enforceable.  The arbitrators shall have no authority to modify any provision of
this Agreement or to award a remedy for a dispute involving this Agreement other
than a benefit specifically provided under or by virtue of the Agreement.  Each
party shall be responsible for its own expenses, unless the Executive shall
prevail in an arbitration proceeding as to any material issue, in which case the
Company shall reimburse the Executive for all reasonable costs, expenses and
fees relating to the conduct of the arbitration, and shall share the fees of the
American Arbitration Association.  The Company shall pay the reasonable costs,
expenses and fees relating to the conduct of the arbitration to the Executive
within thirty (30) days after the date on which it is finally determined that
the Executive has prevailed on any material issue which is the subject of such
arbitration.

9. Survivability.  The respective rights and obligations of the parties under
this Agreement shall survive any termination of the Executive’s employment to
the extent necessary to the intended preservation of such rights and
obligations.

10. Assignment.  All of the terms and provisions of this Agreement shall be
binding upon and inure to the benefit of and be enforceable by the respective
heirs, executors, administrators, legal representatives, successors and assigns
of the parties hereto, except that the duties and responsibilities of the
Executive under this Agreement are of a personal nature and shall not be
assignable or delegable in whole or in part by the Executive.  The Company shall
require any successor (whether direct or indirect, by purchase, merger,

11

--------------------------------------------------------------------------------

 

consolidation, reorganization or otherwise) to all or substantially all of the
business or assets of the Company, within fifteen (15) days of such succession,
expressly to assume and agree to perform this Agreement in the same manner and
to the same extent as the Company would be required to perform if no such
succession had taken place and the Executive acknowledges that in such event the
obligations of the Executive hereunder, including but not limited to those under
Section 6, will continue to apply in favor of the successor.

11. Entire Agreement; Amendment; Waiver.  This Agreement, together with the
Proprietary Information and Invention Assignment Agreement and that certain
Indemnification Agreement by and between the Executive and the Company dated
November 17, 2014, sets forth the entire understanding between the parties
hereto with respect to the subject matter hereof and cannot be changed,
modified, extended or terminated except upon written amendment approved by the
Board and executed on its behalf by a duly authorized officer (other than the
Executive) and by the Executive.  This Agreement supersedes the provisions of
the Prior Agreement (such that the Prior Agreement shall be void and of no
further force and effect) and any other agreement between the Executive and the
Company that relate to any matter that is also the subject of this Agreement.

12. Remedies Cumulative; No Waiver.  No remedy conferred upon a party by this
Agreement is intended to be exclusive of any other remedy, and each and every
such remedy shall be cumulative and shall be in addition to any other remedy
given under this Agreement or now or hereafter existing at law or in equity.  No
delay or omission by a party in exercising any right, remedy or power under this
Agreement or existing at law or in equity shall be construed as a waiver
thereof, and any such right, remedy or power may be exercised by such party from
time to time and as often as may be deemed expedient or necessary by such party
in its sole discretion.

13. Beneficiaries/References.  The Executive shall be entitled, to the extent
permitted under any applicable law, to select and change a beneficiary or
beneficiaries to receive any compensation or benefit payable under this
Agreement following the Executive’s death by giving the Employer written notice
thereof.  In the event of the Executive’s death or a judicial determination of
the Executive’s incompetence, reference in this Agreement to the Executive shall
be deemed, where appropriate, to refer to the Executive’s beneficiary, estate or
other legal representative.

14. Withholding.  All payments under this Agreement shall be made subject to
applicable tax withholding, and the Company shall withhold from any payments
under this Agreement all federal, state and local taxes as the Company is
required to withhold pursuant to any law or governmental rule or
regulation.  The Executive shall bear all expense of, and be solely responsible
for, all federal, state and local taxes due with respect to any payment received
under this Agreement.

15. Indemnification.  The Company agrees to indemnify and hold the Executive
harmless to the fullest extent permitted by the laws of the State of Delaware
and under the bylaws of the Company, both as in effect at the time of the
subject act or omission.  In connection therewith, the Executive shall be
entitled to the protection of any insurance policies which the Company elects to
maintain generally for the benefit of the Company’s directors and officers,
against all costs, charges and expenses whatsoever incurred or sustained by the
Executive in connection with any action, suit or proceeding to which the
Executive may be made a party by reason of his being or having been a director,
officer or employee of the Company.  This provision shall survive any
termination of the Executive’s employment hereunder.

16. Notices.  Any notice or communication required or permitted under the terms
of this Agreement shall be in writing and shall be delivered personally, or sent
by registered or certified mail, return receipt requested, postage prepaid, or
sent by nationally recognized overnight carrier, postage prepaid, or sent by
facsimile transmission to the Company at the Company’s principal office and
facsimile number or to the Executive at the address and facsimile number, if
any, appearing on the books and records of the Company.  Such notice or

12

--------------------------------------------------------------------------------

 

communication shall be deemed given (a) when delivered if personally delivered;
(b) five (5) mailing days after having been placed in the mail, if delivered by
registered or certified mail; (c) the business day after having been placed with
a nationally recognized overnight carrier, if delivered by nationally recognized
overnight carrier, and (d) the business day after transmittal when transmitted
with electronic confirmation of receipt, if transmitted by facsimile.  Any party
may change the address or facsimile number to which notices or communications
are to be sent to it by giving notice of such change in the manner herein
provided for giving notice.  Until changed by notice, the following shall be the
address and facsimile number to which notices shall be sent:

If to the Company, to:

Antares Pharma, Inc.

Princeton Crossroads Corporate Center

100 Princeton South, Suite 300

Ewing, New Jersey 08628

Attn:Chief Executive Officer

(609) 359-3015 (facsimile)

With a copy to:

Morgan, Lewis and Bockius LLP

1701 Market Street

Philadelphia, PA 19103

Attn: Joanne R. Soslow, Esq.

(215) 963-5001 (facsimile)

If to the Executive, to the most recent address on file with the Company or to
such other names or addresses as the Company or the Executive, as the case may
be, shall designate by notice to each other person entitled to receive notices
in the manner specified in this Section 16.

17. Governing Law.  This Agreement will be governed by and construed in
accordance with the laws of the State of New Jersey, without regard to conflict
of law principles.  

18. Counterparts.  This Agreement may be executed in counterparts, each of which
shall be deemed to be an original, but all such counterparts shall together
constitute one and the same instrument.  

19. Headings; Gender.  The headings of sections and subsections herein are
included solely for convenience of reference and shall not control the meaning
or interpretation of any of the provisions of this Agreement.

20. Severability.  If any provision of this Agreement or application thereof to
anyone or under any circumstances is adjudicated to be invalid or unenforceable
in any jurisdiction, such invalidity or unenforceability shall not affect any
other provision or application of this Agreement which can be given effect
without the invalid or unenforceable provision or application and shall not
invalidate or render unenforceable such provision or application in any other
jurisdiction.  If any provision is held void, invalid or unenforceable with
respect to particular circumstances, it shall nevertheless remain in full force
and effect in all other circumstances.

[Signature Page Follows]

13

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and
year first above written.

 

 

ANTARES PHARMA, INC.

 

 

 

 

By:

/s/ Robert F. Apple

 

Name:

Robert F. Apple

 

Its President & CEO

 

 

 

EXECUTIVE:

 

 

 

 

/s/ James E. Fickenscher

 

 

James E. Fickenscher

 

14

--------------------------------------------------------------------------------

 

Exhibit A

SEPARATION AGREEMENT AND RELEASE

This SEPARATION AGREEMENT AND RELEASE (this “Agreement”) is entered into as of
__________, 20___ to be effective on the Effective Date (as defined in Section 1
below), by and between Antares Pharma, Inc. (the “Company”) and James E.
Fickenscher (the “Executive”).  

RECITALS

WHEREAS, pursuant to the terms of an Amended and Restated Employment Agreement,
effective as of June 30, 2016, entered into by and between the Company and
Executive (the “Employment Agreement”), Executive has been employed as the
Company’s Senior Vice President, Chief Financial Officer;

WHEREAS, the Company and Executive have come to a mutual agreement with respect
to Executive’s termination from employment with the Company to be effective
_______________ (the “Termination Date”);

WHEREAS, in connection with Executive’s termination from employment with the
Company, at the request of the Board of Directors of the Company, Executive
resigned as an officer of the Company effective as of the Termination Date; and

WHEREAS, as consideration for Executive’s execution and non-revocation of a
release of all claims against the Company and its affiliates upon the
Termination Date, the Company desires to provide Executive with the severance
payments and benefits set forth in Section 1(a) below following the Termination
Date.

NOW, THEREFORE, in consideration of the mutual promises hereinafter set forth
and intending to be legally bound hereby, the parties hereby agree as follows:

Termination from Employment.  Executive resigns as an officer of the Company as
of the Termination Date.  Executive’s termination from employment with the
Company shall be effective on the Termination Date.  Consistent with Section
3(c) of the Employment Agreement and provided that the terms and conditions set
forth herein are satisfied, Executive shall be entitled to the following:  

Severance Payments and Benefits.  [Based on Non-CIC Related Severance.  To be
modified if termination is following a CIC.]  In consideration of the payments
in this Section 1(a), Executive hereby agrees to execute and not revoke the
General Release of Claims attached hereto as Exhibit A (the
“Release”).  Provided that the Release becomes effective in accordance with the
terms set forth therein (such date the Release becomes effective, the “Effective
Date”), and so long as Executive continues to comply with the provisions of the
Proprietary Information and Invention Assignment Agreement dated June 30, 2016
(defined in Section 6(a) of the Employment Agreement) and the restrictive
covenants and representations in Section 6 of the Employment Agreement,
Executive will receive the following severance payments:

15

--------------------------------------------------------------------------------

 

Continued Base Salary Plus Target Annual Bonus.  The Company will pay Executive
severance as follows:  the rate of the Executive’s Base Salary as in effect at
the time of termination will be added together with the dollar value of the
Executive’s target Annual Bonus for the year in which termination occurs and the
sum of the foregoing amounts will be divided by twelve (12) (the “Monthly
Severance Amount”).  The Monthly Severance Amount will be paid each month over
the twelve (12) month period following the Termination Date, less applicable tax
withholding, paid in approximately equal installments beginning within the sixty
(60)-day period following the date of the Executive’s termination of employment
and continuing on each payroll date thereafter until fully paid, in accordance
with the Company’s regular payroll practices.  The first severance payment will
include any missed payments during such sixty (60)-day period.  

Health Benefits.  For the twelve (12) month period following the Termination
Date, provided that Executive is eligible for, and timely elects COBRA
continuation coverage, the Company will pay on Executive’s behalf, the monthly
cost of COBRA continuation coverage under the Company’s group health plan for
Executive and, where applicable, his spouse and dependents, at the level in
effect as of the Termination Date, less the employee portion of the applicable
premiums that Executive would have paid had he remained employed during the such
twelve (12) month period (the COBRA continuation coverage period shall run
concurrently with the twelve (12) month period that COBRA premium payments are
made on Executive’s behalf under this subsection 1(a)(ii)).  These payments on
Executive’s behalf will commence within the sixty (60)-day period following the
Termination Date and will be paid on the first payroll date of each month
through the twelfth (12th) month following the Termination
Date.  Notwithstanding the foregoing, the Company’s payment of the monthly COBRA
premiums in accordance with this subsection 1(a)(ii) shall cease immediately
upon the earlier of:  (A) the end of twelve (12) month period following the
Termination Date, or (B) the date that Executive is eligible for comparable
coverage with a subsequent employer.  Executive agrees to notify the Company in
writing immediately if subsequent employment is accepted prior to the end of the
twelve (12) month period following the Termination Date and Executive agrees to
repay to the Company any COBRA premium amount paid on Executive’s behalf during
such period for any period of employment during which group health coverage is
available through a subsequent employer.  Notwithstanding the foregoing, the
Company reserves the right to restructure the foregoing COBRA premium payment
arrangement in any manner necessary or appropriate to avoid fines, penalties or
negative tax consequences to the Company or Executive (including, without
limitation, to avoid any penalty imposed for violation of the nondiscrimination
requirements under the Patient Protection and Affordable Care Act or the
guidance issued thereunder), as determined by the Company in its sole and
absolute discretion.

Time-Based Equity Award Acceleration.  All outstanding equity awards held by
Executive immediately prior to the Termination Date granted under the Antares
Pharma, Inc. 2008 Equity Incentive Plan, as amended from time to time (the “2008
Plan”) or a successor plan, which vest based on Executive’s continued services
over time that would have become vested during the twelve (12) month period
following the Termination Date had Executive remained employed during such
twelve (12) month period following Executive’s Termination Date, shall
accelerate, become fully vested and exercisable as of the Termination Date.  All
equity awards that have not vested as of the Termination Date will automatically
terminate and be canceled on the Termination Date, and Executive hereby fully
and forever waives and releases any and all right to such terminated and
canceled equity awards.  Any outstanding vested options held by Executive as of
the Termination Date shall remain exercisable through the earlier of the six (6)
month anniversary of Executive’s Termination Date or the date of the expiration
of the option term.

16

--------------------------------------------------------------------------------

 

20___ Annual Bonus.  The Company will pay Executive the amount of Executive’s
bonus earned for any fiscal year ended prior to Executive’s Termination Date but
for which any bonus earned for such fiscal year has not yet been paid, if any,
less applicable taxes, which will be determined in accordance with Section 2(b)
of the Employment Agreement and will be paid to Executive at the same time and
under the same terms and conditions as such bonus is paid to other executives of
the Company who participate in the Company’s Annual Incentive Plan.

20___ Annual Bonus.  The Company will pay to Executive a pro rata annual bonus
for fiscal year 20___ (the fiscal year in which the Termination Date occurs),
which shall be determined based on Executive’s actual annual bonus earned for
fiscal year 20___, if any, based on actual performance, multiplied by a
fraction, the numerator of which is _________ (representing the number of days
in which Executive was employed by Company during fiscal year 20___), and the
denominator of which is three hundred sixty-five (365).  The pro rata annual
bonus for fiscal year 20___ will be paid at the same time and under the same
terms and conditions as bonuses are paid to other executives of the Company who
participate in the Company’s Annual Incentive Plan, on or after January 1,
20____ but not later than March 15, 20___.

Payment in lieu of Notice.  Without regard to whether Executive executes or
revokes the Release, the Company will pay Executive an amount equal to
$__________, which equals thirty (30) days of base salary, in lieu of the
Company’s obligation to provide notice of termination pursuant to Section 3(c)
of the Employment Agreement, less applicable tax withholding and normal
deductions.  Such amount will be paid to Executive on the Company’s next regular
payroll date after the Termination Date.  

Accrued Wages and Benefits. Without regard to whether Executive executes or
revokes the Release, the Company will pay or provide Executive with any amounts
earned, accrued and owing but not yet paid under Section 2 of the Employment
Agreement including but not limited to base salary for services rendered through
the Termination Date and any benefits accrued and due under any applicable
benefit plans and programs of the Company.  The Company will pay Executive the
amount of $_________ based on ______________ (_____) hours of accrued but unused
vacation. Upon the Executive’s receipt of his final paycheck, which includes
payment for services through the Termination Date and the amount set forth in
the preceding sentence for accrued but unused vacation, Executive will have
received all wages and benefits owed to him by virtue of his employment with the
Company or termination thereof.

Executive is not eligible for any other payments or benefits by virtue of his
employment with the Company or termination thereof except for those expressly
described in this Agreement. Employee will receive the payments described in
Sections 1(b) and 1(c) whether or not he signs this Agreement. Employee will not
receive the separation pay or benefits described in Section 1(a) of this
Agreement if he (i) does not sign this Agreement, (ii) revokes the release of
claims in accordance with the Release, or (iii) violates any of the terms and
conditions set forth in this Agreement.

Restrictive Covenants.  Executive and the Company agree that Section 6 of the
Employment Agreement continues to remain in full force and effect in accordance
with the terms therein and are hereby incorporated by reference.

Non-Admission. It is expressly understood that this Agreement does not
constitute, nor will it be construed as an admission by the Company of any
liability or unlawful conduct whatsoever.  The Company specifically denies any
liability or unlawful conduct.

17

--------------------------------------------------------------------------------

 

Section 409A.  This Agreement is intended to comply with section 409A of the
Internal Revenue Code of 1986, as amended (the “Code”) and its corresponding
regulations, or an exemption, and payments may only be made under this Agreement
upon an event and in a manner permitted by section 409A of the Code, to the
extent applicable.  For purposes of section 409A of the Code, all payments to be
made upon a termination of employment under this Agreement may only be made upon
a “separation from service” within the meaning of such term under section 409A
of the Code, each payment made under this Agreement shall be treated as a
separate payment and the right to a series of installment payments under this
Agreement is to be treated as a right to a series of separate payments.  In no
event shall Executive, directly or indirectly, designate the calendar year of
payment of any severance benefits.  All reimbursements and in-kind benefits
provided under this Agreement shall be made or provided in accordance with the
requirements of section 409A of the Code.

Entire Agreement, Amendment and Assignment.  Except as otherwise provided in a
separate writing between the Company and Executive, this Agreement, including
the attachments hereto, is the sole agreement between the Company and Executive
with respect to the subject matter hereof and it supersedes all prior agreements
and understandings with respect thereto, and all prior agreements and
understandings with respect to his employment with the Company prior to the
Termination Date, whether oral or written, including, but not limited to, the
Employment Agreement (except for Section 6 (including the Proprietary
Information and Invention Assignment Agreement dated June 30, 2016) and 15
therein).  No modification to any provision of this Agreement shall be binding
unless in writing and signed by the Company and Executive.  All of the terms and
provisions of this Agreement shall be binding upon and inure to the benefit of
and be enforceable by the respective heirs, executors, administrators, legal
representatives, successors and permitted assigns of the parties hereto, except
that the duties and responsibilities of Executive hereunder are of a personal
nature and shall not be assignable or delegable in whole or in part by
Executive.

Waiver.  No waiver of any rights under this Agreement shall be effective unless
in writing signed by the party to be charged.  A waiver by any of the parties
hereto of a breach of any provision of this Agreement by another party shall not
operate or be construed as a waiver of any subsequent breach.

Taxes.  All payments under this Agreement shall be made subject to applicable
tax withholding, and the Company shall withhold from any payments under this
Agreement, all federal, state and local taxes as the Company is required to
withhold pursuant to any law or governmental rule or regulation.  Executive
shall bear all expense of, and be solely responsible for, all federal, state and
local taxes due with respect to any payment received under this Agreement.  

Governing Law; Venue.  This Agreement shall be governed in accordance with the
laws of the State of New Jersey, without regard to the conflicts of law or
choice of law principles thereof.  If any dispute between the parties leads to
litigation, the parties agree that the courts of the State of New Jersey or the
federal courts in New Jersey shall have the exclusive jurisdiction and venue
over such litigation.  All parties consent to personal jurisdiction in the State
of New Jersey, and agree to accept service of process outside of the State of
New Jersey as if service had been made in that state.  

18

--------------------------------------------------------------------------------

 

Notices.  All notices, demands or other communications to be given or delivered
under or by reason of the provisions of this Agreement shall be in writing and
shall be deemed to have been given when delivered personally to the recipient,
two business days after the date when sent to the recipient by reputable express
courier service (charges prepaid) or four (4) business days after the date when
mailed to the recipient by certified or registered mail, return receipt
requested and postage prepaid.  Such notices, demands and other communications
shall be sent to Executive and to the Company at the addresses set forth below,

 

If to Executive:

The most recent address in the Company’s files.

If to the Company:

Antares Pharma, Inc.

100 Princeton South

Suite 300

Ewing, NJ 08628

Attn:  Peter J. Graham, Senior Vice President, General Counsel, Chief Compliance
Officer, Human Resources and Secretary

 

With a copy to:

Morgan, Lewis and Bockius LLP

1701 Market Street

Philadelphia, PA 19103

Attn: Joanne R. Soslow, Esq.

(215) 963-5001 (facsimile)

 

or to such other address or to the attention of such other person as the
recipient party has specified by prior written notice to the sending party.

Confidentiality of this Agreement.  Executive agrees not disclose to others the
fact or terms of this Agreement, except Executive may disclose such information
to his spouse or domestic/civil union partner and to his attorney or accountant
(in order for such individuals to render professional services to Executive), so
long as such individuals agree to keep such information confidential.  Nothing
in this Section 10, or elsewhere in this Agreement, is intended to prevent or
prohibit Executive from (a) providing information regarding Executive’s former
employment relationship with the Company, as may be required by law or legal
process, or (b) cooperating, participating or assisting in any government entity
investigation or proceeding.  

Reports to Government Entities.  

Nothing in this Agreement, including the restrictive covenants incorporated
herein or the “Confidentiality of this Agreement” clause, restricts or prohibits
Executive from initiating communications directly with, responding to any
inquiries from, providing testimony before, providing confidential information
to, reporting possible violations of law or regulation to, or from filing a
claim or assisting with an investigation directly with a self-regulatory
authority or a government agency or entity, including but not limited to the
U.S. Equal Employment Opportunity Commission, the Department of Labor, the
National Labor Relations Board, the Department of Justice, the Securities and
Exchange Commission, the Congress, and any agency Inspector General
(collectively, the “Regulators”), or from making other disclosures that are
protected under the whistleblower provisions of state or federal law or
regulation. Please take notice that federal law provides criminal and civil
immunity to federal and state claims for trade secret misappropriation to
individuals who disclose a trade secret to their attorney, a court, or a
government official in certain, confidential circumstances that are set forth at
18 U.S.C. §§ 1833(b)(1) and 1833(b)(2), related to the reporting or
investigation of a suspected violation of the law, or in connection with a
lawsuit for retaliation for reporting a suspected violation

19

--------------------------------------------------------------------------------

 

of the law.  However, Executive is waiving his right to receive any individual
monetary relief resulting from such claims, regardless of whether Executive or
another party has filed them, and in the event Executive obtains such monetary
relief the Company will be entitled to an offset for the payments made pursuant
to this Agreement, except where such limitations are prohibited as a matter of
law (e.g., under the Sarbanes-Oxley Act of 2002, 18 U.S.C.A. §§
1514A).  Executive does not need the prior authorization of the Company to
engage in such communications with the Regulators, respond to such inquiries
from the Regulators, provide confidential information or documents to the
Regulators, or make any such reports or disclosures to the
Regulators.  Executive is not required to notify the Company that Executive has
engaged in such communications with the Regulators.  If the Executive is
required by law or judicial order to disclose confidential information, other
than to Regulators as described above, the Executive shall give prompt written
notice to the Company so as to permit the Company the opportunity to limit or
prevent any such disclosure and to obtain an order of protection or
confidentiality to protect its interests in the confidential information to the
extent possible.  Subject to the foregoing sentence, Executive may furnish that
portion (and only that portion) of the confidential information that Executive
is legally compelled or is otherwise legally required to disclose; provided,
however, that Executive provides such assistance as Company may reasonably
request in obtaining such order or other relief.

Executive recognizes and agrees that, in connection with any such activity
outlined above, Executive must inform the Regulators, Executive’s attorney, a
court or a government official that the information Executive is providing is
confidential.  Despite the foregoing, Executive is not permitted to reveal to
any third-party, including any governmental, law enforcement, or regulatory
authority, information Executive came to learn during the course of Executive’s
employment with the Company that is protected from disclosure by any applicable
privilege, including but not limited to the attorney-client privilege and/or
attorney work product doctrine.  The Company does not waive any applicable
privileges or the right to continue to protect its privileged attorney-client
information, attorney work product, and other privileged information.

Survivability.  The respective rights and obligations of the parties under this
Agreement shall survive termination of Executive’s services hereunder to the
extent necessary to the intended preservation of such rights and obligations.

Counterparts and Electronic Signatures.  This Agreement shall become binding
when any one or more counterparts hereof, individually or taken together, shall
bear the signatures of Executive and the Company.  This Agreement may be
executed in two or more counterparts (including facsimile counterparts or as a
“pdf” or similar attachment to an email), each of which shall be deemed to be an
original as against any party whose signature appears thereon, but all of which
together shall constitute but one and the same instrument.

Severability.  If any provision of this Agreement or application thereof to
anyone or under any circumstances is adjudicated to be invalid or unenforceable
in any jurisdiction, such invalidity or unenforceability shall not affect any
other provision or application of this Agreement which can be given effect
without the invalid or unenforceable provision or application and shall not
invalidate or render unenforceable such provision or application in any other
jurisdiction.

Headings. The headings of sections and subsections appearing in this Agreement
are inserted for convenience only and shall not control the meaning or
interpretation of any provisions of this Agreement.

[Signature Page Follows]

20

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the undersigned, intending to be legally bound, have duly
executed this Agreement as of the date first above written.

 

 

ANTARES PHARMA, INC.

 

 

 

 

By:

 

 

Name:

 

 

Title:

 

 

 

 

 

JAMES E. FICKENSCHER

 

 

 

 

 

21

--------------------------------------------------------------------------------

 

Exhibit A

GENERAL RELEASE OF CLAIMS

In consideration of the severance benefits payable to James E. Fickenscher
(“Executive”) under Section 1(a) of the attached Separation Agreement dated as
of ___________, 20___, by and between Antares Pharma, Inc. (the “Company”) and
Executive (the “Agreement”), the terms of which are incorporated by reference to
this General Release of Claims (this “Release”)), Executive hereby executes this
Release on his own behalf and also on behalf of any heirs, agents,
representatives, successors and assigns that he has now or may have in the
future.  

1. General Waiver & Release.  Executive hereby waives and releases any and all
claims, subject to and without waiving any rights identified in Section 1(c),
whether or not now known to Executive, whether legal, equitable or otherwise,
against the Company, its parent, subsidiary and affiliated companies, and all of
their past and present officers, directors, employees, agents and assigns
(collectively, “Releasees”), arising from or relating to any and all acts,
events and omissions occurring prior to the date Executive signs this Release.

Included Claims.  The claims being waived and released include, without
limitation:

any and all claims arising from or relating to Executive’s recruitment, hire,
employment and termination of employment with the Company;

any and all claims of wrongful discharge, emotional distress, defamation,
misrepresentation, fraud, detrimental reliance, breach of contractual
obligations, promissory estoppel, negligence, assault and battery, violation of
public policy;

any and all claims for monetary damages arising under the Age Discrimination in
Employment Act of 1967 (“ADEA”) as amended, the Older Workers Benefit Protection
Act of 1990 (“OWBPA”), Title VII of the Civil Rights Act of 1964 as amended, and
the Americans with Disabilities Act of 1990 as amended;

any and all claims, outside of those identified in Section (1)(a)(iii), of
unlawful discrimination, harassment and retaliation under applicable federal,
state and local laws and regulations;

any and all claims, outside of those identified in Section (1)(a)(iii), of
violation of any federal, state and local law relating to recruitment, hiring,
terms and conditions of employment, and termination of employment; and

any and all claims for monetary damages and any other form of personal relief.

Unknown Claims.  In waiving and releasing any and all claims, subject to and
without waiving any rights identified in Section 1(c), against the Releasees,
whether or not now known to Executive, Executive understands that this means
that, if Executive later discovers facts different from or in addition to those
facts currently known by Executive, or believed by Executive to be true, the
waivers and releases of this Release shall remain effective in all respects --
despite such different or additional facts and Executive’s later discovery of
such facts, even if Executive would not have agreed to this Release if Executive
had prior knowledge of such facts.

22

--------------------------------------------------------------------------------

 

Exceptions.  Executive may still bring claims:

for unemployment, state disability and/or paid family leave insurance benefits
pursuant to the terms of applicable state law;

for continuation of existing participation in Company-sponsored group health
benefit plans, at Executive’s full expense, under the federal law known as
“COBRA” and/or under an applicable state counterpart law;

for any benefit entitlements that are vested as of the Termination Date pursuant
to the terms of a Company-sponsored benefit plan governed by the federal law
known as “ERISA;”

for any vested stock and/or vested option shares pursuant to the written terms
and conditions of Executive’s existing stock and stock option grants and
agreements, existing as of the Termination Date and for all such rights that are
granted in and survive the Agreement, including accelerated vesting rights;

for violation of any federal, state or local statutory and/or public policy
right or entitlement that, by applicable law, is not waivable;

for any wrongful act or omission occurring after the date Executive signs this
Release;

for any continuing rights to indemnification and defense under Section 13 of the
Employment Agreement and under the Company’s governing documents, by-laws,
policies and insurance policies; and

in his capacity as a stockholder of the Company.

2. Entire Agreement.  This Release and the Agreement contain the entire
agreement of Executive and the Company with respect to the subject matter hereof
and supersede and render null and void any and all prior or contemporaneous oral
or written understandings, statements, representations or promises pertaining to
the matters set forth herein and in the Agreement.  

3. Governing Law; Venue.  This Release shall be governed in accordance with the
laws of the State of New Jersey, without regard to the conflicts of law or
choice of law principles thereof.  If any dispute between the parties leads to
litigation, the parties agree that the courts of the State of New Jersey or the
federal courts in New Jersey shall have the exclusive jurisdiction and venue
over such litigation.  All parties consent to personal jurisdiction in the State
of New Jersey, and agree to accept service of process outside of the State of
New Jersey as if service had been made in that state.  

4. Further Acknowledgements. Executive acknowledges that:

(a) Executive has been offered a period of at least twenty-one (21)1 calendar
days from the date he received this Release within which to review and consider
its terms before signing it;

(b) The Company hereby advises the Executive to consult with an attorney prior
to executing this Release, and he fully understands this right;

 

1 

If the Executive’s employment is terminated as part of a group termination, then
the Executive must be provided with 45 calendar days to consider the Release,
and provided with additional information about the employees considered and
selected for the group termination.

23

--------------------------------------------------------------------------------

 

(c) Executive has carefully read and understands all of the provisions of this
Release and that he is entering into this Release freely, knowingly, and
voluntarily;

(d) Executive is not waiving any rights or claims that may arise after this
Release is executed or any other claims that cannot be waived as a matter of
law;

(e) The consideration provided to Executive in consideration for his execution
of this Release is greater than any benefits to which Executive would have been
entitled had he not executed this Release;

(f) Any changes made to this Release before Executive signs it will not entitle
him to an additional twenty-one (21) calendar days to review the new version of
this Release;

(g) Executive is not entitled to the severance benefits set forth in Section
1(a) of the Agreement, unless he signs and does not revoke this Release;

(h) Executive may revoke this Release within seven (7) calendar days following
its execution (the “Revocation Period”) by notifying the Company in writing, by
certified letter delivered to the attention of Peter J. Graham, Senior Vice
President, General Counsel, Chief Compliance Officer, Human Resources, and
Secretary, Antares Pharma, Inc., 100 Princeton South, Suite 300, Ewing, NJ
08628, and the terms of this Release shall not become effective or enforceable
until the day after the expiration of the Revocation Period; and

(i) Executive is not relying upon any promises, inducements, representations, or
statements that are not expressly set forth in this Release or the Agreement.  

IN WITNESS WHEREOF, Executive, acknowledging that he is acting of his own free
will after receiving a reasonable period of time to consider the terms of this
Release, has caused the execution of this Release as of this day and year
written below.

Agreed and Accepted:

 

James E. Fickenscher

 

Date

 

24

--------------------------------------------------------------------------------

 

Exhibit B

Proprietary Information and Invention Assignment Agreement

ANTARES PHARMA, INC.

PROPRIETARY INFORMATION AND

INVENTION ASSIGNMENT AGREEMENT

As an employee of Antares Pharma, Inc. (the “Company”), I acknowledge that the
Company operates in a competitive environment and that it enhances its
opportunities to succeed by establishing policies designed to identify and
secure the Company’s Intellectual Property and Proprietary Information.  This
Agreement is designed to make clear that:

 

i)

I will maintain the confidentiality of the Company’s Proprietary Information and
use such Proprietary Information for the exclusive benefit of the Company;

 

 

ii)

Inventions that I create will be owned by the Company; and

 

 

iii)

My activities separate from the Company will not conflict with the Company’s
development of its proprietary rights.

 

In consideration of my employment and/or the continuation of my employment by
the Company, I hereby agree as follows:

1.

Provisions Related to Trade Secrets

 

(a)

I acknowledge that the Company possesses and will continue to develop and
acquire valuable Proprietary Information (as defined below), including
information that I may develop or discover as a result of my employment with the
Company.

 

(b)

As used in this Agreement, “Proprietary Information” means any information
(including any compilation, device, method, technique or process) that derives
independent economic value, actual or potential, from not being generally known
to the public or other persons who can obtain economic value from its disclosure
or use, and includes information of the Company, its customers, suppliers, joint
ventures, licensors, licensees, distributors and other persons and entities with
whom the Company does business.

 

(c)

I will not disclose or use at any time, either during or after my employment
with the Company, any Proprietary Information except for the exclusive benefit
of the Company as required by my duties for the Company, as the Company
expressly may consent to in writing or in accordance with Sections 1(d) and (e)
below.  Except as specifically authorized under Sections 1(d) and (e) below, I
will cooperate with the Company to implement reasonable measures to maintain the
secrecy of, and will use my best efforts to prevent the unauthorized disclosure,
use or reproduction of, all Proprietary Information.

25

--------------------------------------------------------------------------------

 

 

(d)

I understand that nothing in this Agreement restricts or prohibits me from
initiating communications directly with, responding to any inquiries from,
providing testimony before, providing confidential information to, reporting
possible violations of law or regulation to, or from filing a claim or assisting
with an investigation directly with a self-regulatory authority or a government
agency or entity, including the U.S. Equal Employment Opportunity Commission,
the Department of Labor, the National Labor Relations Board, the Department of
Justice, the Securities and Exchange Commission, the Congress, and any agency
Inspector General (collectively, the “Regulators”), or from making other
disclosures that are protected under the whistleblower provisions of state or
federal law or regulation.  I understand that I do not need the prior
authorization of the Company to engage in such communications with the
Regulators, respond to such inquiries from the Regulators, provide confidential
information or documents to the Regulators, or make any such reports or
disclosures to the Regulators.  I am not required to notify the Company that I
have engaged in such communications with the Regulators.  If I am required by
law or judicial order to disclose Proprietary Information, other than to
Regulators as described above, I will give prompt written notice to the Company
so as to permit the Company the opportunity to limit or prevent any such
disclosure and to obtain an order of protection or confidentiality to protect
its interests in the Proprietary Information to the extent possible.  Subject to
the foregoing sentence, I may furnish that portion (and only that portion) of
the Proprietary Information that I am legally compelled or otherwise legally
required to disclose; provided, however, that I provide such assistance as
Company may reasonably request in obtaining such protective order or other
relief.  

 

(e)

Federal law provides certain protections to individuals who disclose a trade
secret to their attorney, a court, or a government official in certain,
confidential circumstances.  Specifically, federal law provides that an
individual shall not be held criminally or civilly liable under any federal or
state trade secret law for the disclosure of a trade secret under either of the
following conditions:

 

i)

Where the disclosure is made (A) in confidence to a Federal, State, or local
government official, either directly or indirectly, or to an attorney; and (B)
solely for the purpose of reporting or investigating a suspected violation of
law; or

 

 

ii)

Where the disclosure is made in a complaint or other document filed in a lawsuit
or other proceeding, if such filing is made under seal.  See 18 U.S.C. §
1833(b)(1)).

 

Federal law also provides that an individual who files a lawsuit for retaliation
by an employer for reporting a suspected violation of law may disclose the trade
secret to the attorney of the individual and use the trade secret information in
the court proceeding, if the individual (A) files any document containing the
trade secret under seal; and (B) does not disclose the trade secret, except
pursuant to court order.  See 18 U.S.C. § 1833(b)(2).

 

(f)

Upon leaving employment with the Company for any reason, I immediately will
deliver to the Company any property, records, documents and other tangible
materials (including all copies) in my possession or under my control, including
data incorporated in word processing, computer and other data storage media,
containing or disclosing Proprietary Information, except as otherwise permitted
in accordance with Sections 1(d) and (e) above.

26

--------------------------------------------------------------------------------

 

2.

Ownership of Inventions 

 

(a)

I agree to communicate to the Company as promptly and fully as practicable all
Inventions (as defined below) conceived or reduced to practice by me (alone or
jointly by others) at any time during my employment with the Company.  I hereby
assign to the Company and/or its nominees all my right, title and interest in
such Inventions, and all my right, title and interest in any patents,
copyrights, patent applications or copyright applications based thereon.  I will
give the Company and/or its nominees (at no expense to me) any assistance it
reasonably requires to perfect, protect and use its rights to all such
Inventions anywhere in the world.

 

(b)

As used in this Agreement, the term “Inventions” includes, but is not limited
to, all discoveries, improvements, processes, developments, designs, know-how,
data, computer programs and formulae, whether patentable or unpatentable or
protectable by copyright or other intellectual property law.

 

(c)

Any provision in this Agreement requiring me to assign my rights in any
Invention does not apply to an Invention for which no equipment, supplies,
facility or trade secret information of the Company was used, and which was
developed entirely on my own time, and which:

 

(i)

does not relate directly to the Company’s business or to the Company’s
anticipated research or development, or

 

 

(ii)

does not result from any work performed by me for the Company.

 

 

(d)

I hereby designate and appoint the Company and each of its duly authorized
officers as my agent and attorney-in-fact to act for and in my behalf to execute
and file any document, and to do all other lawfully permitted acts to further
the prosecution, issuance and enforcement of patents, copyrights and other
proprietary rights with the same force and effect as if executed and delivered
by me.

3.

Conflicts With Other Activities

I understand that my employment with the Company and my compliance with this
Agreement do not and will not breach any agreement to keep in confidence any
information acquired by me prior to or outside of my employment with the
Company.  I have not brought and will not bring with me to the Company for use
in the performance of my duties at the Company any materials, documents or
information of a former employer or any third party that are not generally
available to the public unless I have obtained express written authorization
from the owner for their possession and use by or for the Company.  I have not
entered into and will not enter into any agreement, either oral or written, in
conflict with this Agreement.

4.

Miscellaneous

 

(a)

My obligations under this Agreement may not be modified or terminated, in whole
or in any part, except in a writing signed by the Company.  Any waiver by the
Company of a breach of any provision of this Agreement will not operate or be
construed as a waiver of any subsequent breach.  

 

(b)

Each provision of this Agreement will be treated as a separate and independent
clause, and the unenforceability of any one provision will in no way impair the
enforceability of any other provision.  If any provision is held to be
unenforceable, such provision will be construed by the appropriate judicial body
by limiting or reducing it to the minimum extent necessary to make it legally
enforceable.

27

--------------------------------------------------------------------------------

 

 

(c)

My obligations under this Agreement will survive the termination of my
employment, regardless of the manner of such termination.  This Agreement will
inure to the benefit of and will be binding upon the successors and assigns of
the Company. 

 

(d)

I understand that the provisions of this Agreement are a material condition to
my employment and/or continued employment with the Company.  I also understand
that this Agreement is not an employment contract, and nothing in this Agreement
creates any right to my continuous employment by the Company, or to my
employment for any particular term.

 

(e)

Any breach of this Agreement likely will cause irreparable harm to the Company
for which money damages could not reasonably or adequately compensate the
Company.  Accordingly, I agree that the Company will be entitled to injunctive
relief to enforce this Agreement, in addition to damages and other available
remedies.

SIGNING THIS AGREEMENT CREATES IMPORTANT OBLIGATIONS OF TRUST AND AFFECTS THE
EMPLOYEE’S RIGHTS TO INVENTIONS THE EMPLOYEE MAY MAKE DURING HIS/HER EMPLOYMENT.

 

Dated:

 

 

Employee Signature:

 

 

Employee Name:

 

 

 

Printed or typed

 

ACCEPTED AND AGREED TO:

ANTARES PHARMA, INC.

 

 

 

 

By:

 

 

 

 

28